Answers are grounded in this paper and cite their sources.
Introduction Blinatumomab, a bispecific T-cell engager targeting CD19, has approved indications in adult and pediatric B-cell precursor acute lymphoblastic leukemia (B-ALL). Emerging data explored its use outside of B-ALL. This scoping review aimed to summarize the available evidence on the use of blinatumomab outside of B-ALL. Methods A scoping review was performed with systematic search in EMBASE and PubMed from inception and repeated in October 2026. Clinical studies, of any design, that included patients, of any age, who received blinatumomab for indications outside of B-ALL were eligible for inclusion. Efficacy and safety outcomes were reported descriptively according to the disease condition. Design-specific Joanna Briggs Institute (JBI) tools for critical appraisal were used to assess the quality of the included studies. Results Fifty-four eligible studies were included, which varied in design between case reports/series [n = 39] and phase I/II trials [n = 15] and encompassed B-cell non-Hodgkin lymphomas [B-NHL; n = 14], Richter Transformation/chronic lymphocytic leukemia [RT/CLL; n = 5], mixed-phenotype acute leukemia [MPAL; n = 11], blast-phase chronic myeloid leukemia [BP-CML; n = 7], acute myeloid leukemia [AML; n = 3], transplant-related uses [HSCT-r; n = 4] and benign immune-mediated diseases [IMD; n = 10]. In relapsed or refractory B-NHL, overall response rates of 37–43% and complete response rates of 19–22% were reported after one cycle. Responses in Richter transformation were uncommon and short-lived. In BP-CML and MPAL, remissions were described in most case reports, frequently as a bridge to allogeneic transplantation. In IMD, B-cell depletion and short-term clinical improvement were commonly reported, although relapse within months was frequent. Small series described clearance of Epstein–Barr virus and responses in post-transplant lymphoproliferative disorder. Overall, cytokine release syndrome was mostly grade 1–2, whereas neurological events were the most frequent toxicity of concern, particularly with higher-dose B-NHL regimens. Quality assessment indicated a high risk of reporting bias. Conclusion Evidence on off-label use of blinatumomab is heterogeneous and largely uncontrolled. The reported responses should be regarded as hypothesis-generating rather than as evidence of efficacy. Prospective controlled studies are needed before any off-label use can be recommended.
No takes yet. Share an insight, caveat, or question.
Yassin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: